Real world lessons on tyrosine kinase inhibitor response and resistance in CML from a developing country Pakistan
Sahrish Khan, Zafar Iqbal, Muhammad Usman Ghani, Muhammad Farooq Sabar · 2026
Read Real world lessons on tyrosine kinase inhibitor response and resistance in CML from a developing country Pakistan by Sahrish Khan, Zafar Iqbal, Muhammad Usman Ghani, Muhammad Farooq Sabar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624465.txt.
Description
Tyrosine kinase inhibitors have changed chronic myeloid leukemia care, but real-world results in poorer settings may differ from trial results. The four authors reviewed 209 patients treated at Mayo Hospital Lahore between 2022 and 2025. Most, 89.4 percent, were in chronic phase, with a few in accelerated phase or blast crisis. Imatinib was the first drug for 114 patients, though 22 switched to nilotinib after resistance appeared.
Among chronic phase patients, 24.0 percent reached a deep molecular response and 9.6 percent a major one, leaving over two-thirds with incomplete responses despite long therapy. Mutation testing found resistance-linked changes such as G250E and E459K in advanced cases, some with fatal outcomes. Five of the ten blast crisis patients died. The authors conclude the drugs work for a good share of chronic phase patients, but wide variation and resistance in advanced phases call for personalized management.
Catalog record
| CREATOR | Sahrish Khan, Zafar Iqbal, Muhammad Usman Ghani, Muhammad Farooq Sabar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |